In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
615: Tree Soil, Rodent Biologist, Soundscape Artist. Sept 8, 2023, Part 2
614: Embryo Model, Sweat, Whale Vocal Fry. September 8, 2023, Part 1
613: An AI for Smell, Heat and Agricultural Workers, Golden Lion Tamarin, Y Chromosome. Sept 1, 2023, Part 2
612: US Surgeon General On Mental Health, Tracking Tick Bites. Sept 1, 2023, Part 1
611: Old Things Considered: La Brea, Megalodon, Dino Footprints, Surviving History. Aug 25, 2023, Part 2
610: Sea Otters, Alaskan Minerals, Salmon Restoration. Aug 25, 2023, Part 1
609: Women Athletes, Stem Cell Cornea Repair, Sand. August 18, 2023, Part 2
608: Covid Update, Brain Fog Research, Toilet to Tap. Aug 18, 2023, Part 1
Pod Pregnancy Movie, Increase In Deep-Sea Mining, Upcoming Astronomical Delights. August 11, 2023, Part 2
Hawai’i Wildfires, Blue-Fin Tuna Science, Maine’s New Lithium Deposit. August 11, 2023, Part 1
Answering Evolution Questions, Planetary Protection. Aug 4, 2023, Part 2
Artificial Sweetener Safety, Nuclear Weapons Tech. Aug 4, 2023, Part 1
The Cat’s Meow, Chumash Marine Sanctuary, EV Tires. July 28, 2023, Part 2
Kākāpō Conservation, NYC Parrots, One Year After the Dobbs Decision. July 28, 2023, Part 1
How Does The Brain Control Your Every Move? July 21, 2023, Part 1
What To Know Before You Go See ‘Oppenheimer’. July 21, 2023, Part 2
Lab-Grown Meat Approval, Underground Climate Change, Utahraptor. July 14, 2023, Part 2
Youth Mental Health Crisis, Repairing Sharks’ Bad Reputation. July 14, 2023, Part 1
Accessible Birding, Space Sounds, Wasps. July 7, 2023. Part 2
Beavers, Pando Tree, $7 Violin. July 7, 2023. Part 1
Create your
podcast in
minutes
It is Free
The Modern West
Just Dumb Enough Podcast
Voices of Misery Podcast
House of Whimsical Terror
Stuff You Should Know
Timcast IRL